Medical Oncologist, department of oncology at the University hospital of Geneva (HUG). All opinions expressed here are my own
Genève, Suisse
Joined February 2012
- Tweets18.8K
- Following168
- Followers3.1K
- Likes50.8K
Alfredo Addeo MD retweeted
The International Lung Cancer Summit (ILCS) 2026 starts tomorrow, 13 November, at 09:45 CET, with ctDNA first and the debate on first-line ES-SCLC at 16:00, at CHUV in Lausanne and online.
If you have not registered yet, there is still time today. See you tomorrow 🙂
ILCS 2026 faculty: @peters_solange @Alfdoc2 @DasMillie11 @HHorinouchi @TelmaSequeiraMD @christine_lovly @dplanchard @PatelOncology @ACortelliniMD @g_mountzios @a_dingemans
Registration is open: lungsummit.org/registration/
#ILCS2026 #LungCancer #NSCLC #SCLC
Alfredo Addeo MD retweeted
5/ @StephenVLiu on a talk from @Alfdoc2 on the value of adjuvant therapy following neoadjuvant for resectable NSCLC:
xitter.twitterapi.xyz/StephenVLiu/status/211…
Dr. @Alfdoc2 debates the value of adjuvant therapy following neoadjuvant for resectable NSCLC - is there a clear benefit that justifies the excess cost, particularly for those who achieve pCR?
Alfredo Addeo MD retweeted
Can't get to Lausanne on Friday? A free Lung Summit account lets you follow every session of the International Lung Cancer Summit (ILCS) 2026 live online, from 09:45 CET on 13 November.
If you have not registered yet, sign up today so your account is ready on Friday. We look forward to having you with us 🙂
ILCS 2026 faculty: @peters_solange @Alfdoc2 @DasMillie11 @HHorinouchi @TelmaSequeiraMD @christine_lovly @dplanchard @PatelOncology @ACortelliniMD @g_mountzios @a_dingemans
Registration is open: lungsummit.org/registration/
#ILCS2026 #LungCancer #NSCLC #SCLC
Alfredo Addeo MD retweeted
The International Lung Cancer Summit (ILCS) 2026 closes with a panel on patient cases sent in by the audience.
Alfredo Addeo (@Alfdoc2), of Geneva University Hospitals, chairs with Solange Peters (@peters_solange). Send a case at lungsummit.org/patient-cases, and join us on Friday in Lausanne or online.
Registration is open: lungsummit.org/registration/
#ILCS2026 #LungCancer #NSCLC #SCLC
Alfredo Addeo MD retweeted
🫁 Hold, restart, or stop T-DXd? Watch the full roundtable on OncoNexus as Drs. @JSabari and @JuliaRotow discuss how the severity of interstitial lung disease shapes that decision. oncologynexus.com/video/dest… @nyulangone @DanaFarberNews @Alfdoc2 @lungoncdoc @StephenVLiu
Alfredo Addeo MD retweeted
First #ESMO26 highlights episode of the @IASLC podcast Lung Cancer Considered features Drs. @sands_jacob @DrJNaidoo and @FSkoulidis touching on DeLLphi-305, Krascendo 1, and MOIO among others. Very impactful @myESMO meeting for lung cancer!
iaslc.org/iaslc-news/lung-ca…
Alfredo Addeo MD retweeted
The International Lung Cancer Summit (ILCS) 2026 runs this Friday, 13 November, from 09:45 to 17:00 CET at CHUV in Lausanne and live online.
If a colleague is still deciding, please pass the flyer on. We look forward to welcoming you and your colleagues.
ILCS 2026 faculty: @peters_solange @Alfdoc2 @DasMillie11 @HHorinouchi @TelmaSequeiraMD @christine_lovly @dplanchard @PatelOncology @ACortelliniMD @g_mountzios @a_dingemans
Registration is open: lungsummit.org/registration/
#ILCS2026 #LungCancer #NSCLC #SCLC
Alfredo Addeo MD retweeted
📊 DESTINY-Lung04: Frontline T-DXd improved median PFS (14.3 vs 8.3 months) in HER2-mutant NSCLC, with no significant OS benefit.
🫁 Our panel --@JSabari, @JuliaRotow, @Alfdoc2, and Helena Yu -- talks T-DXd vs HER2 TKIs and how ILD severity shapes decisions to hold, restart, or stop treatment.
▶️ Watch on OncoNexus: oncologynexus.com/video/dest…
@DanaFarberNews @nyulangone @MSKCancerCenter
Alfredo Addeo MD retweeted
See my new @bmj_latest editorial about surrogate endpoints ⬇️
Surrogate endpoints can come at the cost of greater uncertainty: improving a surrogate may not improve what ultimately matters to patients.
Can new recommendations on surrogate endpoints lead to meaningful patient benefit?
bmj.com/content/395/bmj-2026…
Alfredo Addeo MD retweeted
Sponsors have no control over, or input into, the scientific content of the International Lung Cancer Summit (ILCS) 2026, and we thank them for the support that makes the day possible.
We meet in Lausanne and online this Friday, 13 November. Thank you to every sponsor, and to everyone who has registered so far.
ILCS 2026 faculty: @peters_solange @Alfdoc2 @DasMillie11 @HHorinouchi @TelmaSequeiraMD @christine_lovly @dplanchard @PatelOncology @ACortelliniMD @g_mountzios @a_dingemans
Registration is open: lungsummit.org/registration/
#ILCS2026 #LungCancer #NSCLC #SCLC
Alfredo Addeo MD retweeted
A real pleasure debating Dr. @BenjaminBesseMD in Porto on the ideal placement of BiTEs like tarlatamab - first line vs maintenance. Great points all around - no question that the future is built on this new class of agents.
Alfredo Addeo MD retweeted
Inaugural Lung Cancer Treatment Controversies in Porto - candid pros & cons circling big decision points & future directions. So appreciative of organization from Drs. Antonio Araujo and Ana Rodrigues and my fellow co-chairs @delvysra @LuisPaz_Ares & all the amazing faculty!
Alfredo Addeo MD retweeted
Proud to support @RManochakian in his candidacy for the #ASCO Nominating Committee! An outstanding colleague and a dedicated leader with a strong commitment to our oncology community. Wishing you every success, Rami! 👏
#Voting for @ASCO Election is now open.
I am #honored & #humbled to be running as one of the candidates, for the #ASCO #NominatingCommittee, alongside many remarkable talented candidates & GREAT colleagues.
Visit asco.org/election to learn more about the candidates & place your vote!
Alfredo Addeo MD retweeted
🎬 In our new #ESMO26 NSCLC roundtable, @JSabari, @Alfdoc2, @HelenaYu923, and @JuliaRotow ask: What comes after progression on targeted therapy?
🧬 KRASCENDO-1: What could divarasib’s PFS and OS gains mean for KRAS G12C treatment sequencing?
🔬 SAFFRON: Why does tissue MET testing matter after osimertinib progression?
Watch our expert panel put the data into context:
▶️ oncologynexus.com/video/esmo…
@MSKCancerCenter
@nyulangone
@hug_ge
@DanaFarber
@BalazsHalmosMD
@lungoncdoc
@StephenVLiu
@DasMillie11
@TejasPatilMD
Alfredo Addeo MD retweeted
Expert perspectives from #ESMO26! 🎙️
In the latest #LungCancerConsidered episode, Drs. @StephenVLiu and @NarjustFlorezMD welcome @DrJNaidoo @sands_jacob and @FSkoulidis to share insights from across the thoracic oncology community.
🎧 Listen now: bit.ly/4BNcJML
#LungCancer #ThoracicOncology
Alfredo Addeo MD retweeted
Badge holders meet in the Agora building at CHUV, and online-pass and free-account holders log in on lungsummit.org: the International Lung Cancer Summit (ILCS) 2026 is a week from today, 13 November, from 09:45 CET in Lausanne.
The day is CME-accredited by SSMO and EACCME. If you have not registered yet, do it this week so your account is ready on the day. See you next Friday 🙂
ILCS 2026 faculty: @peters_solange @Alfdoc2 @DasMillie11 @HHorinouchi @TelmaSequeiraMD @christine_lovly @dplanchard @PatelOncology @ACortelliniMD @g_mountzios @a_dingemans
Registration is open: lungsummit.org/registration/
#ILCS2026 #LungCancer #NSCLC #SCLC
Alfredo Addeo MD retweeted
12,323 Chinese physicians joined virtually for “Scientific Roundtable: DeLLphi-305 Study” recorded in Madrid studio and broadcast after ESMO 2026. Many thanks to our outstanding speakers for sharing their expertise and insights.
@sands_jacob @Alfdoc2
#DeLLphi305 #DeLLphi #SCLC
Alfredo Addeo MD retweeted
Celebration of Hope and Progress- how special to be able to jointly celebrate Ross Camidge as this year’s Face of Hope awardee and his continued achievements as a true leader of our field- now both as a brilliant clinician-scientist and a most authentic patient/patient advocate!
Introduced beautifully by @christine_lovly, Ross’ special call to us all clinicians/industry alike tonite was to ensure that we treat EVERY patient we face in clinic and EVERY “event” on a survival curve as it could be ourselves.
Hope and progress- compassion and science intertwined!
@LUNGevity
Pleased to share my thoughts with colleagues @JSabari, @JuliaRotow and Helena Yu as we discuss some of the key findings presented at #ESMO2026, focusing on KRAScend-1 and SAFFRON.
Exciting developments in targeted therapies for #NSCLC, but also important questions that remain unanswered.
🎥 oncologynexus.com/video/esmo…
1
15
637
